Chromatographic purity
0.05 M Ammonium phosphate buffer
Dissolve 5.75 g of monobasic ammonium phosphate in 1000 mL of water, and adjust with phosphoric acid to a pH of 3.00 ± 0.05.
Solution A
Prepare a filtered and degassed mixture of 0.05 M Ammonium phosphate buffer and acetonitrile (97:3).
Solution B
Prepare a filtered and degassed mixture of 0.05 M Ammonium phosphate buffer and acetonitrile (4:1).
Mobile phase
Use variable mixtures of
Solution A and
Solution B as directed for
Chromatographic system. Make adjustments if necessary (see
System Suitability under
Chromatography 621).
Resolution solution
Dissolve an accurately weighed quantity of
USP Naratriptan Resolution Mixture RS in water to obtain a solution having a known concentration of about 0.11 mg per mL.
Test solution
Dissolve an accurately weighed quantity of Naratriptan Hydrochloride in water to obtain a solution having a known concentration of about 0.11 mg per mL.
Chromatographic system (see Chromatography 621)
The liquid chromatograph is equipped with a 225-nm detector and a 4.6-mm × 15-cm column that contains 4-µm packing L1. The column temperature is maintained at 40
. The flow rate is about 1.5 mL per minute. The chromatograph is programmed as follows.
Time (minutes) |
Solution A
(%) |
Solution B
(%) |
Elution |
035.0 |
100®0 |
0®100 |
linear gradient |
35.040.0 |
0 |
100 |
isocratic |
40.041.0 |
0®100 |
100®0 |
linear gradient |
41.051.0 |
100 |
0 |
re-equilibration |
Chromatograph the
Resolution solution, and record the peak responses as directed for
Procedure: the relative retention times are about 1.04 for
2-[3-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-5-yl]ethanesulfonic acid methylamide (naratriptan related compound B) and 1.0 for naratriptan; and the resolution,
R, between naratriptan and naratriptan related compound B is not less than 1.5.
Procedure
Inject a volume (about 20 µL) of the
Test solution into the chromatograph, record the chromatogram, and measure the areas for all of the peaks. Calculate the percentage of each impurity in the portion of Naratriptan Hydrochloride taken by the formula:
100(ri /F)/[rN + S(ri /F)],
in which
F is the relative response factor (see the accompanying table for values) for each impurity;
ri is the peak response for each impurity; and
rN is the naratriptan peak response (see the accompanying table for limits).
Compound Name |
Relative Retention Time |
Relative Response Factor (F) |
Limit (%) |
3-(1-Methylpiperidin-4-yl)-1H-indole |
about 0.93 |
1.0 |
0.2 |
2-[3-(1-Methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indol- 5-yl]ethanesulfonic acid methylamide |
about 1.04 |
0.6 |
0.1 |
2,2-Bis-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl] ethanesulfonic acid methylamide |
about 1.18 |
0.6 |
0.2 |
1-Methyl-4-[5-(2-methylsulfamoyl-ethyl)-1H-indol- 3-yl]-pyridinium chloride |
about 1.25 |
0.4 |
0.2 |
2-[3-(1-Methylpiperidin-4-yl)-5-(2-methylsulfamoyl- ethyl)-indol-1-yl]ethanesulfonic acid methylamide |
about 1.36 |
0.6 |
0.3 |
4-[1,5-Bis-(2-methylsulfamoyl-ethyl)-1H-indol-3-yl]-1- methylpyridinium chloride |
about 1.44 |
0.5 |
0.1 |
2-[3-(1-Methylpiperidin-4-yl)-1H-indol-5-yl]ethane- sulfonic acid methyl-(2-methylsulfamoyl- ethyl)amide |
about 1.48 |
1.0 |
0.2 |
5-Ethyl-3-(1-methylpiperidin-4-yl)-1H-indole |
about 1.90 |
1.00 |
0.2 |
In addition to not exceeding the limits listed in the accompanying table, not more than 0.1% of any other individual impurity is found; and not more than 1.5% of total impurities is found.
Assay
0.01 M Triethylamine phosphate buffer
Dilute 0.6 mL of phosphoric acid with water to 900 mL, and adjust with triethylamine to a pH of 2.5.
Mobile phase
Prepare a filtered and degassed mixture of
0.01 M Triethylamine phosphate buffer and isopropyl alcohol (9:1). Make adjustments if necessary (see
System Suitability under
Chromatography 621).
Resolution solution
Dissolve accurately weighed quantities of USP Naratriptan Hydrochloride RS and
USP Naratriptan Resolution Mixture RS in
Mobile phase to obtain a solution having known concentrations of about 0.11 mg per mL and 0.11 µg per mL, respectively.
Standard preparation
Dissolve an accurately weighed quantity of USP Naratriptan Hydrochloride RS in Mobile phase, and dilute quantitatively, and stepwise if necessary, with Mobile phase to obtain a solution having a known concentration of about 0.11 mg per mL.
Assay preparation
Transfer about 11 mg of Naratriptan Hydrochloride, accurately weighed, to a 100-mL volumetric flask, dissolve in and dilute with Mobile phase to volume, and mix.
Chromatographic system (see Chromatography 621)
The liquid chromatograph is equipped with a 282-nm detector and a 4.6-mm × 15-cm column that contains 3-µm packing L11. The column temperature is maintained at 35
. The flow rate is about 1.5 mL per minute. Chromatograph the
Resolution solution, and record the peak responses as directed for
Procedure: the relative retention times are about 0.9 for 3-(1-methylpiperidin-4-yl)-1
H-indole (naratriptan related compound A), 1.0 for naratriptan, and 1.1 for naratriptan related compound B; and the resolution,
R, between naratriptan related compound A and naraptriptan and between naratriptan related compound B and naratriptan is not less than 1.5. Chromatograph the
Standard preparation, and record the peak responses as directed for
Procedure: the relative standard deviation for replicate injections is not more than 1.5%.
Procedure
Separately inject equal volumes (about 10 µL) of the
Standard preparation and the
Assay preparation into the chromatograph, record the chromatograms, and measure the areas for the major peaks. Calculate the quantity, in mg, of C
17H
25N
3O
2S·HCl in the portion of Naratriptan Hydrochloride taken by the formula:
100C(rU / rS),
in which
C is the concentration, in mg per mL, of USP Naratriptan Hydrochloride RS in the
Standard preparation; and
rU and
rS are the peak responses obtained from the
Assay preparation and the
Standard preparation, respectively.